{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:24:26Z","timestamp":1792268666975,"version":"4.4.0"},"reference-count":20,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myelofibrosis (MF) is associated with several constitutional symptoms. Currently, there are few therapeutic options for MF. Jaktinib, a novel, small\u2010molecule inhibitor of JAK, is currently being studied for its potential to treat MF. This phase 2 trial investigated efficacy and safety of jaktinib in the treatment of MF patients. The primary end point was the proportion of patients with \u226535% reduction in spleen volume (SVR35, proportion of patients with \u226535% reduction in spleen volume) at week 24. The secondary end points included improvement of anemia, rates of symptom response, and safety profile. Between January 8, 2019 and August 29, 2020, 118 patients were recruited and treated with either jaktinib 100\u2009mg BID or 200\u2009mg QD. At week 24, 54.8% (34\/62) of patients in the 100\u2009mg BID group and 31.3% (15\/48) in the 200\u2009mg QD group achieved SVR35 (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.0199). Jaktinib treatment increased hemoglobin level to \u226520\u2009g\/L in 35.6% (21\/59) of patients with hemoglobin \u2264100\u2009g\/L at baseline. The proportion of patients who achieved a \u226550% improvement in total symptom score at week 24 was 69.6% (39\/56) in the BID group and 57.5% (23\/40) in the QD group. The most common \u2265 grade 3 hematological treatment\u2010emergent adverse events (TEAEs; \u2265\u200910%) were anemia (100\u2009mg BID: 24.2%, 200\u2009mg QD: 28.8%), thrombocytopenia (16.7%, 11.5%), and neutropenia (3.0%, 11.5%). All non\u2010hematological TEAEs were mild. These results indicate that jaktinib can shrink the spleen, improve anemia, and other clinical symptoms with good tolerability.<\/jats:p>","DOI":"10.1002\/ajh.26709","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T18:03:41Z","timestamp":1661709821000},"page":"1510-1519","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Safety and efficacy of jaktinib in the treatment of Janus kinase <scp>inhibitor\u2010na\u00efve<\/scp> patients with myelofibrosis: Results of a phase <scp>II<\/scp> trial"],"prefix":"10.1002","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3625-2288","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou P.R. China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou P.R. China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders  Hangzhou P.R. China"},{"name":"Zhejiang University Cancer Center  Hangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital  Zhengzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxing","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Zhengzhou University  Zhengzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengshu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology Xiangya Hospital, Central South University  Changsha P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-0551","authenticated-orcid":false,"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking Union Medical College Hospital (Dongdan Campus)  Beijing P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center The First Hospital of Jilin University  Changchun P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[{"name":"Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease Beijing Key Laboratory of Hematopoietic Stem Cell  Beijing P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology Hematology The Second Hospital of Jilin University  Changchun P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology Sir Run Run Shaw Hospital, Zhejiang University School of Medicine  Hangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-3828","authenticated-orcid":false,"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology West China Hospital, Sichuan University  Chengdu P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology The Second Hospital of Shanxi Medical University  Taiyuan P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences  Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Nanchang University  Nanchang P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Anhui Medical University  Hefei P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital of Bengbu Medical College  Bengbu P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-2544","authenticated-orcid":false,"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology Fujian Medical University Union Hospital  Fuzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The First Hospital of China Medical University  Shenyang P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-4568","authenticated-orcid":false,"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College Huazhong University of Science and Technology  Wuhan P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Third Xiangya Hospital of Central South University  Changsha P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghao","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology Jiangxi Provincial People's Hospital  Nanchang P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology Henan Provincial People's Hospital  Zhengzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology The Second Affiliated Hospital of Kunming Medical University  Kunming P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Suzhou Zelgen Biopharmaceuticals Co, Ltd  Suzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou P.R. China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou P.R. China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders  Hangzhou P.R. China"},{"name":"Zhejiang University Cancer Center  Hangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology The First Affiliated Hospital, Zhejiang University School of Medicine  Hangzhou P.R. China"},{"name":"Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy Zhejiang University  Hangzhou P.R. China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders  Hangzhou P.R. China"},{"name":"Zhejiang University Cancer Center  Hangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25230"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0077-1"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25777"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-020-00596-z"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S212559"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.604314"},{"issue":"10","key":"e_1_2_9_12_1","first-page":"858","article-title":"Efficacy and safety of JAK inhibitor ruxolitinib in Chinese patients with myelofibrosis: results of a 1\u2010year follow\u2010up of A2202","volume":"37","author":"Jin J","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30237-5"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04002-9"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0447-9"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1657093"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26709","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26709","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T21:04:02Z","timestamp":1692479042000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1002\/ajh.26709"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26709","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"2022-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}